ArticleSkin appendage disorders2025
Responsiveness of the Dermatology Life Quality Index and the Colombian Validated Version of the Skindex-29 in Scarring and Non-Scarring Alopecia.
Article in Skin appendage disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alopecia is a frequent reason for consultation and is often associated with psychological, self-esteem, and quality of life (QoL) impact, particularly in women. To date, QoL assessment studies including all alopecia types are lacking. This study evaluated QoL and sensitivity to change of the Skindex-29 and the Dermatology Life Quality Index (DLQI) in these. Methods: This was an observational study with a longitudinal design, including two measurements over time and prospective data. It was carried out in four outpatient centers in Medellín, between 2023 and 2024. We included sociodemographic and clinical data, as well as the DLQI and Skindex-29 QoL questionnaires before and after treatment. Results: Participation of women was 51%; the most frequent types of alopecia were androgenic alopecia (52%), alopecia areata (AA) (19%), and telogen effluvium (TE) (9%). The alopecia types with the greatest impact on QoL (pretreatment) measured through the DLQI and the Skindex-29, respectively, were TE (10.29 [±9.32] and 40.39 [±32.04]), AA (9.27 [±9.13], and 33.91 [±26.47]), dissecting cellulitis (8.67 [±8.33] and 29.6 [±15.33]), and lichen planus pilaris (6.75 [±6.55] and 6.75 [±6.55]). Conclusion: The version validated in Colombia of the Skindex-29 and the Colombian Spanish version of the DLQI showed a moderate responsiveness when evaluating the QoL of patients with scarring and non-scarring alopecia, before and after starting specific treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.